Anitha Jayaprakash

Girihlet

As a PhD student at the Icahn School of Medicine, Anitha developed and patented multiple technologies related to next generation sequencing for the applications of immune, mitochondrial, and small RNA sequencing. In fact, her sRNA-seq patent was licensed and commericalized by Bioo Scientific and has become the top selling sRNA-seq kit on the market. Anitha's T-cell receptor-related patents served as the basis for the immunotherapy startup (Girihlet) that she co-founded and of which she is the CEO. Girihlet uses T-Cell Receptors from the immune system as biomarkers because they can give a dynamic, up-to-date read out of what attacks (both internal and external in origin) the body is currently encountering. They are specific to each person. This has potential applications in diagnosing, monitoring, and treating disease.
SynBioBeta is the leading community of entrepreneurs, investors, policymakers and enthusiasts devoted to the responsible growth of the synthetic biology field. We’re dedicated to telling the stories of the field and companies involved, building their networks, and helping them grow.
Get Social
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram